Want to see SE:ONCOZ full AI Analyst Report?

OncoZenge AB (ONCOZ) Price & Analysis

0 Followers

ONCOZ Stock Chart & Stats

kr5.51

kr0.40(6.64%)

At close: Mar 06 4:00 PM EST

kr5.51

kr0.40(6.64%)

Day’s Range― - ―

52-Week Rangekr4.52 - kr10.28

Previous CloseN/A

Volume9.67K

Average Volume (3M)35.93K

Market Cap

kr92.30M

Enterprise Valuekr79.68

Total Cash (Recent Filing)kr935.00K

Total Debt (Recent Filing)kr7.50M

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding14,048,068

10 Day Avg. Volume29,683

30 Day Avg. Volume35,930

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1

Revenue Forecast (FY)kr10.00M

Bulls Say, Bears Say

Bulls Say

Focused Product: BupiZenge™ For Oral MucositisA single, well-defined product targeting oral mucositis aligns the company with a durable oncology supportive-care need. Focused indication simplifies clinical/regulatory strategy and market messaging, enabling clearer partnering or targeted commercialization paths that persist beyond short-term cycles.

Monetization Via Commercialization And PartneringA partner-friendly business model creates multiple durable revenue pathways (direct sales or licensing with upfront/milestones/royalties). This structure allows capital-efficient scaling, leverages partners' commercial reach, and reduces the need for full-scale internal infrastructure long-term.

Positive Gross Profit Reported In TTMPositive TTM gross profit indicates the product can cover direct costs at current volumes, demonstrating intrinsic margin potential. If fixed R&D and SG&A are controlled or offset via partnerships, this supports sustainable gross-margin expansion as sales scale over months to years.

Bears Say

Minimal And Falling Revenue BaseAn extremely small and sharply declining revenue base signals weak commercial traction or pre-commercial status, creating high execution risk. With near-zero recurring sales, the company cannot rely on product cash flow to fund operations, making long-term planning contingent on new deals or launches.

Persistent Heavy Cash BurnSustained negative operating cash flow and material free cash burn require recurrent external funding. Over a multi-month horizon this constrains strategic options, increases dilution or debt needs, and can delay commercialization or R&D milestones critical to long-term viability.

Very High Leverage And Weak Equity BaseThe sharp shift to meaningful debt on a tiny equity base creates elevated solvency risk and limited financial flexibility. Interest and principal obligations will pressure cash flow, raise refinancing risk, and reduce bargaining power in potential licensing or partnership negotiations.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

1M ago

8LY

ONCOZ FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was kr4.51 and its highest was kr10.28 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is kr92.30M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 19 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on May 20, 2026. The company reported -kr0.538 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,048,068 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -kr0.538 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.735%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in SE:ONCOZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).